Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bisoprolol + rosuvastatin
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bisoprolol + rosuvastatin is a fixed-dose combination of two pharmaceutical agents used primarily for cardiovascular risk management. Bisoprolol is a cardioselective beta-1 adrenergic receptor antagonist (beta blocker) that reduces heart rate, cardiac output, and blood pressure by competitively inhibiting beta-1 adrenergic receptors in the heart and decreasing renin secretion from the kidneys[4]. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol levels by inhibiting the enzyme responsible for cholesterol biosynthesis in the liver, leading to reduced plasma LDL and VLDL concentrations[5][6]. The combination targets both hypertension/heart failure (via bisoprolol) and hyperlipidemia/cardiovascular risk reduction (via rosuvastatin), making it suitable for patients requiring both blood pressure and lipid control. Fixed-dose combinations may improve adherence in patients with comorbid conditions[3].
- Brand names
- Birowon
- Other names
- bisoprolol hemifumarate + rosuvastatin calcium
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ADRB1 (β1)
Beyond the preview
Go deeper on Bisoprolol + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bisoprolol + rosuvastatin.